View of Gilteritinib as a New Option for the Treatment of Relapsed/Refractory Acute Myeloid Leukemias with FLT3 Gene Mutation: A Literature Review and Three Case Reports | Clinical Oncohematology

← Gilteritinib as a New Option for the Treatment of Relapsed/Refractory Acute Myeloid Leukemias with FLT3 Gene Mutation: A Literature Review and Three Case Reports